We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
JPMorgan (JPM) Beats on Q4 Earnings & Revenue Estimates
Read MoreHide Full Article
Have you been eager to see how JPMorgan (JPM - Free Report) performed in Q4 in comparison with the market expectations? Let’s quickly scan through the key facts from this New York-based major global bank’s earnings release this morning:
An Earnings Beat
JPMorgan came out with earnings of $2.57 per share, which surpassed the Zacks Consensus Estimate of $2.32.
Improved non-interest income were partly offset by a rise in expenses.
How Was the Estimate Revision Trend?
You should note that the earnings estimate revisions for JPMorgan depicted optimistic stance prior to the earnings release. The Zacks Consensus Estimate moved nearly 1% upward over the past seven days.
JPMorgan have an impressive earnings surprise history. Before posting the earnings beat in Q4, the company delivered positive surprises in three of trailing four quarters, as shown in the chart below:
Overall, the company has a positive earnings surprise of 4.4% in the trailing four quarters.
Revenue Higher Than Expected
JPMorgan recorded revenues of $28.3 billion, which beat the Zacks Consensus Estimate of $27.3 billion. Also, it compared favorably with the year-ago number of $26.1 billion.
Key Q4 Statistics:
Investment banking fees were up 2% year over year
Fixed Income Markets revenue surged 86% year over year
Equity Markets revenues grew 15% year over year
Mortgage banking fees jumped 133% from the prior-year quarter
Net interest income down 1% year over year
Provisions for credit losses declined 8% year over year
Core loans down 2% year over year
Returned nearly $9.5 billion to shareholders through dividends and share buybacks
Basel III common equity Tier 1 ratio of 12.4%, as of Dec 31, 2019
What Zacks Rank Says
The estimate revisions that we discussed earlier have driven a Zacks Rank #2 (Buy) for JPMorgan. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
Following the earnings release, JPMorgan’s shares are up almost 2% in the pre-trading session. This is in sync with to what the stock witnessed in the prior-day’s session. Clearly, the initial reaction shows that the investors have considered the results in their favor. However, the full-session’s price movement may indicate a different picture.
Check back later for our full write up on this JPMorgan earnings report!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
JPMorgan (JPM) Beats on Q4 Earnings & Revenue Estimates
Have you been eager to see how JPMorgan (JPM - Free Report) performed in Q4 in comparison with the market expectations? Let’s quickly scan through the key facts from this New York-based major global bank’s earnings release this morning:
An Earnings Beat
JPMorgan came out with earnings of $2.57 per share, which surpassed the Zacks Consensus Estimate of $2.32.
Improved non-interest income were partly offset by a rise in expenses.
How Was the Estimate Revision Trend?
You should note that the earnings estimate revisions for JPMorgan depicted optimistic stance prior to the earnings release. The Zacks Consensus Estimate moved nearly 1% upward over the past seven days.
JPMorgan have an impressive earnings surprise history. Before posting the earnings beat in Q4, the company delivered positive surprises in three of trailing four quarters, as shown in the chart below:
JPMorgan Chase & Co. Price and EPS Surprise
JPMorgan Chase & Co. price-eps-surprise | JPMorgan Chase & Co. Quote
Overall, the company has a positive earnings surprise of 4.4% in the trailing four quarters.
Revenue Higher Than Expected
JPMorgan recorded revenues of $28.3 billion, which beat the Zacks Consensus Estimate of $27.3 billion. Also, it compared favorably with the year-ago number of $26.1 billion.
Key Q4 Statistics:
What Zacks Rank Says
The estimate revisions that we discussed earlier have driven a Zacks Rank #2 (Buy) for JPMorgan. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
How the Market Reacted So Far
Following the earnings release, JPMorgan’s shares are up almost 2% in the pre-trading session. This is in sync with to what the stock witnessed in the prior-day’s session. Clearly, the initial reaction shows that the investors have considered the results in their favor. However, the full-session’s price movement may indicate a different picture.
Check back later for our full write up on this JPMorgan earnings report!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>